Anupam Rasayan India Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lkliarjwdsthyh6jaz93z7s4.pdf

Key Takeaways


Revenue Growth & Product Engine

Anand Desai: "This growth was driven by 3 important factors. The first factor was commercialization of 5 new products during the year; second thing is steady growth of our organic product portfolio and third was strong performance by Tanfac."

Order Book & New LOI Wins

Vishal Thakkar: "These are the products which are typically manufactured by customer existing today or maybe sourcing from Europe and other geographies. These are the products which are not being manufactured or sourced from India."

Fluorination Strategy

Vishal Thakkar: "Once they have seen that shockwave, they really believe that they have to finally alternate and they have to do, as there are various words for that like BCP and other, but they would do that."

Margins & Profitability

Vishal Thakkar: "It's just the scheduling and the product mix that we would see."

Balance Sheet & Capital Allocation

Kiran Patel: "I can assure all of our shareholders that we will continue to be cautious and selective in evaluation of these opportunities. And like the acquisition of Tanfac, we will acquire companies only if they are strategic and value accretive to Anupam."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthRobust growth on a standalone basis, consistent with historical trajectoryNext 3 to 5 years
Product launchesOver 10 new products across segments including niche pharmaFY24
New LOI commercializationAt least 2 molecules from the new fluorination LOIsFY24
New LOI full ramp-upBalance of molecules from new LOIs fully rampedFY26 or 2 years thereafter
EBITDA margin26% to 28%Ongoing
Fluorine revenue share20% of portfolioFY24
Fluorine revenue share30% of portfolioFY27
Inventory daysBelow FY21 level of 222 daysFY24
Capex₹350 to 400 croresFY24
Brownfield capex₹670 crores for 3 projects to service LOI requirementsOver next 3 to 5 years
R&D team size175 scientistsFY24
Asset turnover on new capexOver 1.75xOn new capex

Key Metrics

MetricQ4 FY23
Consolidated operating revenue₹480 crore, up 48% YoY
Standalone operating revenue₹1,284 crore, up 20% YoY
Consolidated EBITDA₹141.6 crore, up 46% YoY; margin at 28%
Consolidated EBITDA margin (standalone, excl. other income)Declined ~400 bps QoQ (per an analyst's math)
Consolidated profit after tax₹72.6 crore, up 58% YoY
Full-year consolidated operating revenue₹1,601.9 crore, up 49% YoY
Full-year consolidated EBITDA₹439.9 crore, up 41% YoY; margin at 27%
Full-year consolidated profit after tax₹216.8 crore, up 42% YoY
Cash flow from operations₹244 crore generated during the year
Cash on books₹551 crore as of March 31, 2023
Capex incurred₹177 crore during FY23
Capex guidance₹350 crore to ₹400 crore for FY24
Budgeted capex for 3 brownfield projects₹670 crore total, to be spent over FY24–FY25
Cumulative LOIs and contracts₹5,500 crore, to be supplied over 5 to 7 years
Inventory days250 days, improved from 291 days in FY22
Fluorine-based business contribution~15% of portfolio currently; expected to reach 20%–25% in 2–3 years
R&D team size88 professionals, grew by 11 scientists in FY23
Products commercialized5 new products during FY23; target of over 10 in FY24
Revenue from earlier LOIs commercialized~₹100 crore from 4 molecules commercialized
Top 10 customer concentration82% of total revenue, across 24 products
Export share64% of revenue
Solar power capacity17.9 MW installed, expected savings of ₹14 crore per annum